SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
Key Facts: FDA has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of focal seizures in adults. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2027. The...
Key Facts: FDA has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of focal seizures in adults. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2027. The...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.